Articles Tagged with
A pilot study suggests that exposure to green light of a particular wavelength and brightness may be as effective as drugs in reducing the frequency and severity of migraine. Read more.
A pilot study suggests that exposure to green light of a particular wavelength and brightness may be as effective as drugs in reducing the frequency and severity of migraine. Read more.
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced the publication of a new real-world post-marketing surveillance study in Pain Medicine that demonstrates the safety, efficacy and consistency of the company’s Nerivio® therapeutic wearable device. Full story.
Migraine is a severe and debilitating neurologic disorder and is claimed to be the sixth disabling illness in the world. This study aimed to determine the overall prevalence of restless legs syndrome (RLS) in patients with migraine through a systematic review and meta-analysis. Full story.
There is histological evidence of microstructural changes in the zygomaticotemporal branch of the trigeminal nerve in migraineurs. This raises the possibility that altered trigeminal nerve properties contribute to migraine pathophysiology. Whilst it is not possible to explore the anatomy of small trigeminal nerve branches it is possible to explore the anatomy of the trigeminal root entry zone using magnetic resonance imaging in humans. The aim of this investigation is to assess the microstructure of the trigeminal nerve in vivo to determine if nerve alterations occur in individuals with episodic migraine.
Abstract: Objective: To test the hypotheses that insufficient duration, high fragmentation, and poor sleep quality are temporally associated with migraine onset on the day immediately following the sleep period (day 0) and the following day (day 1).
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-07, Axsome’s novel, oral, multi-mechanistic investigational medicine for the acute treatment of migraine, met the two regulatory co-primary endpoints and significantly improved migraine pain and most bothersome symptoms as compared to placebo in the MOMENTUM Phase 3 trial.
The U.S. Food and Drug Administration approved Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Reyvow is not indicated for the preventive treatment of migraine.
Bring awareness and recognition of headache disorder as a legitimate neurobiological disease and help make individuals with headache disorder know that there are new treatments available. Read about the AAPM Foundation’s Migraine Consensus Guideline project and join AAPM’s Headache and Orofacial Pain Medicine Shared Interest Group.
In honor of National Migraine & Headache Awareness Month, the following related on-demand educational sessions, which were originally presented in conjunction with the AAPM 2018 and 2019 Annual Meeting, can be viewed for free in the AAPM Education Center during the month of June:
Theranica, a bio-medical technology company developing advanced electroceuticals for migraine and other pain disorders, announced today that the U.S. Food and Drug Administration (FDA) granted a De Novo request for its smartphone-controlled electroceutical, Nerivio Migra®, utilizing Remote Electrical Neuromodulation for the acute treatment of migraine.
© American Academy of Pain Medicine. All Rights Reserved.
American Academy of Pain (AAMP) is a nonprofit, 501(c)(3) tax-exempt organization.
1705 Edgewater Drive, #7778
Orlando, FL 32804
Phone: (800) 917-1619 Ext. 102
Fax: (407) 749-0714
American Academy of Pain Medicine
